1. Vidailhet M, Yelnik J, Lagrange C, Fraix V, Grabli D, Thobois S, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol. 2009; 8:709–17.
Article
2. Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004; 94:275–86.
3. Bhidayasiri R. Dystonia: genetics and treatment update. Neurologist. 2006; 12:74–85.
4. Kim AR, Chang JW, Chang WS, Park ES, Cho SR. Two-year outcomes of deep brain stimulation in adults with cerebral palsy. Ann Rehabil Med. 2014; 38:209–17.
Article
5. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85:129–35.
Article
6. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009; 10:136–40.
Article
7. Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005; 20:322–34.
Article
8. Nicholson D, Chiu W. Neuroleptic malignant syndrome. Geriatrics. 2004; 59:36. 38-40.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washinton: American Psychiatric Association;2000. p. 795–8.
10. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142:1137–45.
11. Pranzatelli MR. Oral pharmacotherapy for the movement disorders of cerebral palsy. J Child Neurol. 1996; 11 Suppl 1:S13–22.
Article
12. DeLong M, Wichmann T. Deep brain stimulation for movement and other neurologic disorders. Ann N Y Acad Sci. 2012; 1265:1–8.
Article
13. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord. 1998; 13 Suppl 3:119–25.
Article
14. Vercueil L, Krack P, Pollak P. Results of deep brain stimulation for dystonia: a critical reappraisal. Mov Disord. 2002; 17 Suppl 3:S89–93.
Article
15. Counelis GJ, Simuni T, Forman MS, Jaggi JL, Trojanowski JQ, Baltuch GH. Bilateral subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MER and postoperative MRI with neuropathological findings. Mov Disord. 2003; 18:1062–5.
Article
16. Urasaki E, Fukudome T, Hirose M, Nakane S, Matsuo H, Yamakawa Y. Neuroleptic malignant syndrome (parkinsonism-hyperpyrexia syndrome) after deep brain stimulation of the subthalamic nucleus. J Clin Neurosci. 2013; 20:740–1.
Article
17. Perry D, Birthi P, Salles S, McDowell S. Neuroleptic malignant syndrome associated with the use of carbidopa/levodopa for dystonia in persons with cerebral palsy. PM R. 2012; 4:383–4.
Article
18. Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991; 27:381–4.
19. Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015; 13:395–406.
Article